AOTMiT: Transparency Council will address off-label indications, drug programs and health policy programs

The agenda includes:

1. Preparation of a position paper on the evaluation of the drug Ocrevus (ocrelizumabum) under drug program B.29. "Treatment of patients with multiple sclerosis (ICD-10: G35)".
2. Preparation of an opinion on the draft health policy program of the local government unit "Health policy program on vitamin D deficiency among the inhabitants of the Mazovian province".
3. Preparation of an opinion on continuation of reimbursement in off-label indications for medicinal products containing the active substance Vigabatrinum in the indication: paroxysmal conditions in the course of tuberous sclerosis - monotherapy.
4. Preparation of an opinion on the continuation of reimbursement in off-label indications for medicinal products containing the active substance Acidum mycophenolicum in the indication: condition after transplantation of a limb, cornea, tissue or cells.
5. Preparation of an opinion on continuation of reimbursement in off-label indications for medicinal products containing the active substance Azathioprinum in the indication: condition after transplantation of a limb, cornea, tissue or cells.
6. Preparation of an opinion on continuation of reimbursement in off-label indications for medicinal products containing the active substance Everolimusum in the indication: condition after transplantation of a limb, cornea, tissue or cells.

Source: AOTMiT